Cancer Focused Clovis Oncology Files For Bankruptcy
Cancer Focused Clovis Oncology Files For Bankruptcy
专注于癌症的克洛维斯肿瘤学申请破产
- Clovis Oncology Inc (NASDAQ:CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
- The Debtors have filed various "first day" motions with the Bankruptcy Court requesting customary relief that will enable them to transition into Chapter 11 without material disruption to their ordinary course operations.
- Related: Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms.
- Clovis has received a commitment of up to $75 million in a multi-draw debtor-in-possession (DIP) financing facility.
- Before the Chapter 11 filing, and subject to Bankruptcy Court approval, Clovis entered into a "stalking horse" purchase and assignment agreement with Novartis Innovative Therapies AG for FAP-2286 for an upfront payment of $50 million and up to an additional $333.75 million as development & regulatory milestones and $297 million in later sales milestones.
- Clovis is also actively engaged in discussions with several interested parties for a potential sale of one or more of its other assets.
- Price Action: CLVS shares are down 11.50% at $0.18 during the premarket session on the last check Monday.
- 克洛维斯肿瘤学公司 纳斯达克股票代码：CLVS）已自愿在美国破产法院启动第11章程序，并将寻求通过法院监督的销售程序出售其资产。
- 债务人已向破产法院提交了各种 “第一天” 动议，要求获得惯例救济，使他们能够在不严重干扰其正常课程运作的情况下过渡到第11章。
- 相关： 随着潜在的破产申请的临近，Clovis Oncology股价暴跌。
- 克洛维斯已获得多笔债务人持股（DIP）融资机制中高达7500万美元的承诺。
- 在提交第11章申请之前，经破产法院批准，克洛维斯与诺华创新疗法股份公司签订了 FAP-2286 的 “跟踪马” 收购和转让协议，预付5000万美元，另外支付最高3.3375亿美元作为开发和监管里程碑，以及2.97亿美元的后续销售里程碑。
- 克洛维斯还积极与多个利益相关方就可能出售其一项或多项其他资产进行讨论。
- 价格走势： 在周一的最后一次盘前交易中，CLVS股价下跌了11.50％，至0.18美元。